State of Michigan Retirement System Trims Holdings in Eli Lilly and Company $LLY

State of Michigan Retirement System lowered its stake in shares of Eli Lilly and Company (NYSE:LLY) by 15.9% in the first quarter, Holdings Channel reports. The institutional investor owned 215,804 shares of the company’s stock after selling 40,900 shares during the quarter. Eli Lilly and Company accounts for approximately 1.0% of State of Michigan Retirement System’s portfolio, making the stock its 15th biggest position. State of Michigan Retirement System’s holdings in Eli Lilly and Company were worth $198,490,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. M.E. Allison & CO. Inc. boosted its stake in Eli Lilly and Company by 0.7% during the 4th quarter. M.E. Allison & CO. Inc. now owns 1,477 shares of the company’s stock valued at $1,587,000 after acquiring an additional 10 shares during the last quarter. Tanager Wealth Management LLP increased its position in shares of Eli Lilly and Company by 2.6% in the 4th quarter. Tanager Wealth Management LLP now owns 395 shares of the company’s stock worth $424,000 after purchasing an additional 10 shares during the last quarter. Morey & Quinn Wealth Partners LLC raised its stake in shares of Eli Lilly and Company by 1.5% in the 4th quarter. Morey & Quinn Wealth Partners LLC now owns 661 shares of the company’s stock valued at $710,000 after purchasing an additional 10 shares in the last quarter. Wealthspan Partners LLC lifted its position in shares of Eli Lilly and Company by 0.5% during the fourth quarter. Wealthspan Partners LLC now owns 2,110 shares of the company’s stock worth $2,268,000 after purchasing an additional 10 shares during the last quarter. Finally, G&S Capital LLC lifted its position in shares of Eli Lilly and Company by 2.0% during the fourth quarter. G&S Capital LLC now owns 501 shares of the company’s stock worth $538,000 after purchasing an additional 10 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Down 0.2%

Shares of Eli Lilly and Company stock opened at $1,185.71 on Tuesday. The company has a current ratio of 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of 1.26. The business’s 50 day simple moving average is $1,103.63 and its 200-day simple moving average is $1,034.03. The stock has a market capitalization of $1.12 trillion, a price-to-earnings ratio of 42.12, a PEG ratio of 1.47 and a beta of 0.51. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,249.45.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.97 by $1.58. The business had revenue of $19.80 billion for the quarter, compared to the consensus estimate of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The business’s revenue was up 55.5% on a year-over-year basis. During the same quarter last year, the business posted $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Equities research analysts forecast that Eli Lilly and Company will post 35.81 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date is Friday, August 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 24.58%.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Guggenheim raised its price target on Eli Lilly to $1,273 and reiterated a Buy rating, reinforcing Wall Street’s confidence in the company’s growth outlook. Benzinga
• Positive Sentiment: Eli Lilly is presenting new Kisunla data at the Alzheimer’s Association International Conference, giving investors another potential pipeline catalyst beyond its blockbuster weight-loss drugs. Benzinga
• Positive Sentiment: Commentary around Eli Lilly’s obesity drugs continues to highlight how important the franchise is to revenue, with two products now generating nearly two-thirds of sales — a reminder of the company’s scale and earnings power. The Motley Fool
• Neutral Sentiment: Cathie Wood’s ARK funds added Eli Lilly alongside other large-cap names, which may signal continued institutional interest but is not a direct company-specific catalyst. Yahoo Finance
• Neutral Sentiment: Social-media and trading chatter remains upbeat, with investors citing upgraded targets and biotech momentum, but these comments are sentiment-driven rather than new fundamental disclosures. Quiver Quantitative
• Neutral Sentiment: A 247WallSt piece argues there may be a new under-the-radar catalyst in Eli Lilly’s pipeline, but it is largely speculative and not a confirmed development. 247WallSt

Analyst Upgrades and Downgrades

A number of research firms recently commented on LLY. The Goldman Sachs Group reiterated a “buy” rating and issued a $1,283.00 price target on shares of Eli Lilly and Company in a research note on Friday, May 22nd. Bank of America increased their target price on Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the stock a “buy” rating in a report on Friday. JPMorgan Chase & Co. lifted their target price on Eli Lilly and Company from $1,300.00 to $1,400.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 7th. Weiss Ratings upgraded Eli Lilly and Company from a “buy (b-)” rating to a “buy (b)” rating in a report on Wednesday, July 1st. Finally, Leerink Partners upped their price target on Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the company an “outperform” rating in a research report on Thursday, June 25th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $1,268.78.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.